AR and polycystic ovary syndrome: These findings underscore the significance of distinguishing between circulating and tissue‐resident immune cells and align with existing studies demonstrating phenotypic and functional differences among immune populations within these compartments.[27, 28, 29, 30, 31] Importantly, the co‐treatment with flutamide, an AR antagonist used for the treatment of hyperandrogenism and hirsutism in women with PCOS,[9] enabled us to conclude that these effects on the immune cells were dependent on AR activation.